Announcements Trials
Browse Landscape

Phase

Phase 3 2

Status

Completed 2

Sponsor Class

OTHER 1INDUSTRY 1

Study Type

Interventional 2

Sponsor

Cancer Type

Thoracic 1

Conditions

Recurrence 1Carcinoma, Non-Small-Cell Lung 1

Interventions

Carboplatin 27pembrolizumab 26Cisplatin 24Paclitaxel 21Nivolumab 19Gemcitabine 16Pemetrexed 14Rituximab 14Ipilimumab 12Cyclophosphamide 11Dexamethasone 11Fluorouracil 10Capecitabine 9Docetaxel 9durvalumab 9trastuzumab deruxtecan 9Lenalidomide 8Oxaliplatin 8atezolizumab 8Doxorubicin 7daratumumab 7osimertinib 7Bortezomib 6Cytarabine 6Leucovorin 6Trastuzumab 6olaparib 6venetoclax 6130-nm albumin-bound paclitaxel 5Ado-Trastuzumab Emtansine 5

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Has announcements × Drug Therapy × 1 year × Clear all
NCT03409614 2026-05-18

Combinations of Cemiplimab (Anti-PD-1 Antibody) and Platinum-based Doublet Chemotherapy in Patients With Lung Cancer

Regeneron Pharmaceuticals

Phase 3 Completed
789 enrolled 32 charts 1 FDA
Thoracic

Carcinoma, Non-Small-Cell Lung

NCT03581786 2025-09-02

The Efficacy and Safety Study of TORIPALIMAB INJECTION Combined With Chemotherapy for Nasophapyngeal Cancer

Shanghai Junshi Bioscience Co., Ltd.

Phase 3 Completed
289 enrolled 32 charts 1 FDA

Recurrence

Data powered by HemOnc (CC BY 4.0) Colophon âš¡